Effect of metastasectomy and doxorubicin dose on the outcome of patients with metastastic leiomyosarcoma: A multicenter study

10580 Background: The role of metastasectomy and front-line chemotherapy modalities remain debated in the metastastatic soft tissue sarcoma setting. Methods: Data from 147 M-LMS patients (1988–2008) reviewed in 6 French centers were retrospectively analyzed. Prognostic factors for progression-free and overall survivals (PFS and OS) were identified using log-rank tests and Cox multivariate analysis. The respective impact of treatment modalities on PFS and OS were assessed after adjustment to prognostic factors. Results: This database included 46 (31%) uterus and 101 soft-tissues (69%) M-LMS. All patients received doxorubicin as front-line regimen associated with ifosfamide in 78 cases (53%) or dacarbazine in 56 cases (38%). The planned dose of doxorubicin was > 60 mg/m2/3 weeks in 24 patients (16%). After front-line chemotherapy, 36 patients with lung metastasis (24%) underwent subsequent complete metastasectomy. The median PFS was 6 months. The univariate analysis identified the following prognostic facto...